A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Terminated

Phase 2 Results N/A

Eligibility Criteria

Inclusion Criteria

Males & females age 40-90 years
Enrolled in study within 6 hours of onset of stroke symptoms
Willing to sign informed consent form
No significant disabilities prior to stroke

Exclusion Criteria

Treatment with t-PA (tissue plasminogen activator)
Premorbid modified rankin scale score of 2 or more